GMO Commentary: Value vs. Growth Reversals

By the Asset Allocation Team

Author's Avatar
Jul 13, 2021
Summary
  • The best three-year period for value vs. growth also suffered some of its worst drawdowns.
Article's Main Image

Read original report with charts here.

  • The Value vs. Growth reversal, which started in earnest in the late Fall of 2020, generated exciting returns for many of our portfolios through May. In June, however, the reversal did a reversal, with Growth notably beating Value. It was true across the globe but particularly pronounced in the U.S., as the Russell 1000 Value underperformed Growth by 742 bps. Drawdowns like these are unpleasant, but importantly, from an investor’s mental health perspective, they can be unnerving. The second-guessing starts, questions mount about whether Value’s run was short-lived, and an uncomfortable feeling of “is that it?” arises.
  • Fear not. These profitable trades never happen in a straight line, as history shows.
  • See the first chart above, which shows the historic 3-year reversal of Value vs. Growth from 2000 to 2003. This was the best period in U.S. history. It began for sound reasons, similar to today – the valuation gap between Value and Growth had reached absurd levels by 1999, and mean reversion was inevitable. A long Value/short Growth portfolio would have generated returns of 86% (p.s., it kept being profitable for years afterwards).
  • But it was not a straight line. There were uncomfortable, second-guessing-inducing give-backs along the way. In fact, when we look at the entire 40-year history of the Value vs. Growth relationship (the second chart), 4 of the 10 worst drawdowns ironically occurred during this best 3-year run. If any investors had lost their nerve during any one of these drawdowns, they would have also lost out on the trade of a lifetime.
  • We are not letting a June give-back weaken our resolve, as it was well within expectations. Our thesis remains intact. Value still deserves to win, by a lot. We’ve only just begun.
Disclaimer: The views expressed are the views of the GMO Asset Allocation team through the period ending July 2021 and are subject to change at any time based on market and other conditions. This is not an offer or solicitation for the purchase or sale of any security and should not be construed as such. References to specific securities and issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities.

Disclosures

I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure